AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1959859
Drug: Parenteral amino
RxNorm normalized name: parenteral amino acid 7 % comb no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral amino acid administration (2 l/day of a solution of dextrose (65 gm/L) and amino acids (25.8 gm/L) for 1 month)
Trial: 1959859
Drug: Control (dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (dextrose solution only)
Trial: 27572830
Drug: TAK-063 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 (1000 mg)
Trial: 27572830
Drug: TAK-063 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 (100 mg) under fed conditions
Trial: 27572830
Drug: TAK-063 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 (various doses)
Trial: 21909815
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of batroxobin and TXA (group D)
Trial: 17663820
Drug: Insulin enteric-coated
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin enteric-coated soft capsules (50 IU)
Trial: 17663820
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (15 IU)
Trial: 8211801
Drug: Theopek taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theopek taken twice daily
Trial: 8211801
Drug: Euphylong taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphylong taken in a single daily dose
Trial: 3082230
Drug: metrifonate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metrifonate (10 mg/kg body weight, twice)
Trial: 3082230
Drug: oxamniquine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxamniquine (60 mg/kg)
Trial: 31835620
Drug: Zanthoxylum armatum
RxNorm normalized name: ZANTHOXYLUM ARMATUM FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanthoxylum armatum (ZA) extract (single dose on Day 1)
Trial: 24473958
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion group (CIG)
Trial: 24473958
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion group (IIG)
Trial: 16525751
Drug: Yogurt (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt (375 g/d)
Trial: 16525751
Drug: Semi-skimmed milk
RxNorm normalized name: Calcium fortified semi-skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-skimmed milk (400 ml/d)
Trial: 9684746
Drug: Ubiquinone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinone supplementation (180 mg daily)
Trial: 31421838
Drug: Thermal ablation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal ablation (radiofrequency ablation and endovenous laser therapy)
Trial: 6635761
Drug: Praziquantel 25
RxNorm normalized name: PRAZIQUANTEL 25 kg in 25 kg POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 25 mg/kg
Trial: 19921358
Drug: Intrathecal injection
RxNorm normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of 0.5% isobaric bupivacaine, 2.8 ml plus morphine, 0.05 mg (Group B)
Trial: 19921358
Drug: Intrathecal injection
RxNorm normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of 0.5% isobaric bupivacaine, 2.8 ml (Group A)
Trial: 15041008
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with Xylocain solution
Trial: 9066031
Drug: Liquid combination
RxNorm normalized name: liquid paraffin, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid combination of DTP-PRP-T vaccine
Trial: 22135493
Drug: Routine pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine pharmacological treatment (Control)
Trial: 16267842
Drug: Piribedil 150
RxNorm normalized name: piribedil
DrugBank: Piribedil (DB12478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil 150 mg/day
Trial: 29802820
Drug: 400g red
RxNorm normalized name: Red gum
DrugBank: Eucalyptus gum (DB15537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400g red raspberries (403 mg total (poly)phenols)
Trial: 23479592
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg lycopene/day
Trial: 21130359
Drug: Acupuncture as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture as an adjunct therapy
Trial: 14608833
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg daily for 6 months
Trial: 12221217
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (SP) 40 g daily for 3 months
Trial: 12629084
Drug: Milk-based protein
RxNorm normalized name: milk protein concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based protein (MBP) 40 g daily for 3 months
Trial: 12080805
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation (15 g daily)
Trial: 12080805
Drug: Glycine supplementation
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine supplementation (25 g daily)
Trial: 8649051
Drug: ATRA (all-trans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRA (all-trans retinoic acid) plus chemotherapy
Trial: 1754467
Drug: IVIgG 400
RxNorm normalized name: IVIgGM
DrugBank: Pentaglobin (DB15865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIgG 400 mg/kg b.w. on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months (group B)
Trial: 1754467
Drug: CyA 5‐10/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA 5‐10/kg b.w. by mouth in two daily doses for a period between 6 and 18 months (group C)
Trial: 6626436
Drug: diclofensine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofensine 50 mg
Trial: 6626436
Drug: diclofensine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofensine 25 mg
Trial: 3921328
Drug: Simethicone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone (two tablets)
Trial: 6813959
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets)
Trial: 30893070
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplement
Trial: 26047963
Drug: High flavanol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanol drink (494 mg)
Trial: 16579996
Drug: Goserelin 10.8
RxNorm normalized name: goserelin 10.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 10.8 mg administered 24 hours after UAE
Trial: 3780284
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg betahistine dihydrochloride
Trial: 18455082
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg daily for 7 years)
Trial: 18455082
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 7 years)
Trial: 16647439
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium administration during donor evaluation (coronary angiography or levography)
Trial: 16647439
Drug: No contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No contrast medium administration during donor evaluation
Trial: 9178844
Drug: Ketamine (0.83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.83 mg/ml, 6 ml)
Trial: 1389240
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime (CFX) 1.5 g and metronidazole (MTR) 1.0 g at induction of anaesthesia (Group C)
Trial: 1389240
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime (CFX) 1.5 g on induction of anaesthesia (Group D)
Trial: 1389240
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime (CFX) 1.5 g on induction of anaesthesia then CFX 750 mg bd for 2 days (Group E)
Trial: 3901631
Drug: Hemosorption treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemosorption treatment (n=90)
Trial: 3901631
Drug: No hemosorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hemosorption treatment (n=50)
Trial: 18279877
Drug: Delayed oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oral intake (DOI) group - clear liquid drink given 8 hours after surgery
Trial: 18279877
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral intake (EOI) group
Trial: 18279877
Drug: Delayed oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oral intake (DOI) group
Trial: 17302256
Drug: Interferon plus
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon plus ribavirin therapy
Trial: 12898010
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg B2036‐PEG
Trial: 12898010
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg B2036‐PEG
Trial: 11885185
Drug: Hydroxyapatite (HA)-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite (HA)-coated implants
Trial: 6419593
Drug: Auranofin, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin, 3 mg twice daily
Trial: 3903735
Drug: No dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dietary change after withdrawal from drugs (Group II)
Trial: 3903735
Drug: Continued drug
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued drug treatment (Group III)
Trial: 22749332
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral suctioning (COS) using a saliva ejector connected to 100mmHg of suction.
Trial: 22749332
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral suctioning (COS) using a saliva ejector.
Trial: 17222282
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of abstinence achieved during treatment
Trial: 9247454
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-10 (0.5, 1, 5, 10, or 25 micrograms/kg) administered once daily by intravenous bolus injection over 7 consecutive days
Trial: 9247454
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily by intravenous bolus injection over 7 consecutive days
Trial: 6452806
Drug: Zimelidine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine 100 mg (divided dose)
Trial: 29256407
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium lactate (360 mg elemental magnesium)
Trial: 9266953
Drug: Glycosylated G-CSF
RxNorm normalized name: Glycosylated recombinant G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosylated G-CSF (5 microg/kg/d)
Trial: 8345034
Drug: CGS 20
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20 267 (0.02 mg to 30 mg)
Trial: 8345034
Drug: CGS 20
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20 267 (0.02 mg)
Trial: 8345034
Drug: CGS 20
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20 267 (30 mg)
Trial: 8345034
Drug: CGS 20
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20 267 (10 mg and 30 mg)
Trial: 8345034
Drug: CGS 20
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20 267 (up to 30 mg)
Trial: 8345034
Drug: CGS 20
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 20 267 (all doses)
Trial: 27562916
Drug: Exenatide (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (acute infusion)
Trial: 10356074
Drug: 500 microgram
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microgram folic acid tablet taken with 100 g wheat bran cereal (high folate control)
Trial: 31237871
Drug: Azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20 mg/kg oral suspension)
Trial: 21570139
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration oxygen at 15 L/min via a non-rebreather mask
Trial: 21570139
Drug: Air at
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air at 15 L/min via a non-rebreather mask
Trial: 9850350
Drug: Continuous NaF
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous NaF 50 mg/day with calcium 2000 mg/day for a mean of 15 months (10 with vitamin D, 16 without)
Trial: 9850350
Drug: Cyclical low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclical low-dose NaF alternating with vitamin D for a mean of 15 months and total treatment duration of 28 months
Trial: 4947494
Drug: Isoniazid 400
RxNorm normalized name: isoniazid 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 400 mg daily for 1 year (second year maintenance) in patients with residual cavitation.
Trial: 25326090
Drug: Darunavir/ritonavir 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir 600/100 mg twice daily (n=6)
Trial: 25326090
Drug: Darunavir/ritonavir 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir 800/100 mg once daily (n=17)
Trial: 25326090
Drug: Darunavir/ritonavir 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir 600/100 mg once daily (n=1)
Trial: 21173171
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) concentrations (ng/mL)
Trial: 30268470
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus cisplatin combination therapy
Trial: 15760536
Drug: Cranial hypothermia
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial hypothermia treatment started within 6 hours (Group A)
Trial: 2651251
Drug: Molsidomine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (2 x 2 mg)
Trial: 319871
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (4 mug/kg)
Trial: 23511682
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of contrast medium (Group A)
Trial: 23511682
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of contrast medium (Group B)
Trial: 23511682
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of contrast medium (Group C)
Trial: 15312252
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day of isosorbide mononitrate (ISMO)
Trial: 15312252
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day of isosorbide mononitrate (ISMO)
Trial: 30518633
Drug: Tumor-infiltrating lymphocyte
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-infiltrating lymphocyte (TIL) therapy
Trial: 24480603
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (moderate pressure stroking)
Trial: 20228679
Drug: Intravenous glucagon‐like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucagon‐like peptide‐1 (1.2 pmol/kg/min)
Trial: 16088097
Drug: Ethanol +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol + honey (0.5 g/kg + 1.25 ml/kg)
Trial: 363255
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy to the regional lymph node area following lymphadenectomy
Trial: 19672567
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/day (n=13)
Trial: 17088163
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care for depression (12 months of systematic depression care including antidepressant pharmacotherapy and/or problem-solving treatment)
Trial: 7869886
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) 300 mg.kg‐1
Trial: 7869886
Drug: NaCl 207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 207 mg.kg‐1
Trial: 3257532
Drug: Sulfamethoxazole and
RxNorm normalized name: sulfamethoxazole and trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole and trimethoprim (800 mg and 160 mg twice per day)
Trial: 28615258
Drug: Package of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Package of health and nutrition interventions (lipid nutrient supplement, deworming medication, zinc supplementation, bed net, malaria chemoprophylaxis)
Trial: 25783161
Drug: Beclomethasone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone (40 μg twice daily)
Trial: 21410628
Drug: Linagliptin plus
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin plus pioglitazone (30 mg pioglitazone plus 5 mg linagliptin)
Trial: 12673681
Drug: Peptide MAGE‐A12:170‐178
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide MAGE‐A12:170‐178 administered subcutaneously in incomplete Freund's adjuvant (IFA), either every week or every 3 weeks for 4 cycles.
Trial: 10780138
Drug: Telephone-administered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive-behavioral therapy (CBT) - Coping with MS (CMS)
Trial: 8776821
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 30 mg intravesical instillations weekly for 8 weeks, followed by monthly maintenance doses for 12 months
Trial: 29880238
Drug: Amisulpride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (100 mg daily)
Trial: 29880238
Drug: Amisulpride (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (continued treatment)
Trial: 17036029
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin 1 mg/kg every 8 h
Trial: 9156785
Drug: TCV-309 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV-309 (1.0 mg/kg twice daily for 7 days)
Trial: 6240787
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of spectinomycin intramuscularly
Trial: 6240787
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g of thiamphenicol (500 mg intramuscularly after oral 2 g)
Trial: 29424731
Drug: Cardiac shock
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac shock wave therapy (CSWT)
Trial: 18833117
Drug: Piracetam as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam as a monotherapy in daily dosage 50‐70 mg/kg for 6 weeks
Trial: 18833117
Drug: No pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacological therapy
Trial: 11921128
Drug: Suspension (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension (2.5 mg doses)
Trial: 9885797
Drug: Ondansetron (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (acute treatment)
Trial: 9885797
Drug: Ondansetron (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (chronic administration)
Trial: 22320335
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of availability, labeling, and price reduction